Clinical Trial Update: Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating imatinib mesylate in combination with temozolomide for malignant glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Imatinib mesylate (Imatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED